At the ESMO 2024 Congress in Barcelona, Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented findings from a phase 2 study on BL-B01D1, a novel EGFR and HER3 bispecific ADC designed to treat locally advanced or metastatic urothelial carcinoma. This innovative therapy demonstrated an objective response rate (ORR) of 43.5% and a disease control rate (DCR) of 91.3% in patients who had already undergone prior treatments. The results indicate potential efficacy and manageable safety, with adverse events like anemia and decreased appetite remaining manageable. The study marks a significant step forward in offering new hope for UC patients resistant to traditional therapies.
